C. Glenn Begley

M.B., B.S., Ph.D., F.R.A.C.P., F.R.C.P.A., F.R.C.Path., F.A.H.M.S.

Dr Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development.

He served as Chief Scientific Officer at Akriveia Therapeutics, California (2016-2027) and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016).  From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen’s 5 research sites.  There he highlighted the issue of research integrity and scientific reproducibility. Since then he has made multiple presentations on the subject of scientific integrity including to President Obama’s Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, the British Broadcasting Company, Wellcome Trust, Australian National Health and Medical Research Council, and numerous Universities, Research Institutes and companies.

Before Amgen he had over 20 years of clinical experience in medical oncology and hematology.  His personal research focused on regulation of hematopoietic cells and translational clinical trials.  His early studies, in Prof Donald Metcalf’s department first described human G-CSF, and in later clinical studies, performed in Professor Richard Fox’s Department at the Royal Melbourne Hospital, the group first demonstrated that G-CSF-“mobilized” blood stem cells hastened hematopoietic recovery, a finding that revolutionized bone-marrow transplantation.

His honors include being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, to the Association of American Physicians in 2008, and in 2014 to the Research “Hall of Fame” at his alma mater, the Royal Melbourne Hospital and to the Australian Academy of Health and Medical Sciences.

Dan Deaver

During my academic career I fostered important research collaborations both within and outside the university related to drug development. These efforts required the generation of robust data packages. In the late 1980s, I worked closely with the Upjohn Company during their development of recombinant bovine somatotropin. During the early 1990s I developed an extensive research collaboration with Zetachron, Inc. to study transport of drugs across mucosal membranes using their proprietary drug delivery systems. While this effort ended when Zetachron was acquired by Watson Pharmaceuticals, it provided the foundation for me to collaborate with Dr. David Edwards in the Department of Chemical Engineering at Penn State. Edwards and I co-developed a gel-based drug technology that was out-licensed by Penn State, and eventually developed and approved by the FDA as a veterinary product (OvuGelTM). In addition, I played a key role in assisting Edwards in the development of large porous particle technology for delivery of steroids and proteins by inhalation. Advanced Inhalation Research (AIR) was spun-out of Penn State in late 1997. I joined AIR as a consultant in 1998, while closing down my academic laboratory for a permanent move to AIR in early 1999. Alkermes, Inc acquired AIR for approximately $120,000,000 shortly before I started, and AIR continued to operate as a largely independent subsidiary for about the next 18 months. As AIR was fully integrated into Alkermes my roles evolved overtime. In 2007, I was promoted to Vice-President of Nonclinical R&D. In this capacity I provided leadership and scientific oversight for all biological aspects of nonclinical R&D. I was directly involved with three programs that lead to marketed drugs – Vivitrol®, Bydureon®and Aristada®. Also, I was actively involved in the oversight of medicinal chemistry, pharmacology and toxicology efforts directed towards expanding Alkermes internal drug portfolio. Underscoring all of these activities was the critical importance of generating robust nonclinical research packages to increase the likelihood of a drug reaching market. My demonstrated success in this regard highlights the skillset that I bring to this project.

Rob Miller

Rob Miller has 17 years of biopharma commercial experience with Lilly, Abbott and AbbVie that provides the PAASP US team with an in-depth understanding of how future PAASP biopharma customers develop risk-adjusted valuations for both internal and external innovation:

    •New product commercial development and for over 40 neuroscience programs

    •Commercial forecasts and valuations for over 25 licensing/acquisition assessments

    •Market research projects with over 1,500 HCPs, 300 patients and 250 payers

Rob’s commercial experience also includes seven years of medical product sales and account management with Baxter Healthcare plus account-based consulting and sales with health information firm Sachs Group / Solucient. As a Regional Director Rob managed licensing agreements with large US health systems and academic medical centers. Account based sales and licensing agreements will be directly relevant for building the US PAASP customer base and generating revenue.Rob is currently Vice President, Strategic Initiatives, with Thresholds, which is a behavioral health service provider based in Chicago.  Thresholds generates over $90 million in annual revenue and Rob is responsible for leading initiatives to diversify and grow revenue beyond state Medicaid including Substance Use Disorders and programs for early psychosis and young adults with an SMI diagnosis. 

Patricia Kabitzke

I obtained my PhD from the City University of New York in Neuroscience, followed by a Postdoctoral fellowship at the Columbia university in New York. During the latter, I completed two projects: 1.) I investigated the neural mechanisms underlying the innate fear response early in life, examining the function of components of the fear circuit by blocking the actions of the primary inhibitory neurotransmitter (GABA) in three different regions of the medial prefrontal cortex (mPFC). 2.) I developed novel assays of sociality in rodents and investigating the congenital overexpression of the D2 receptor on social interaction. Following my postdoctoral training, I joined PsychoGenics, a contract research organization, where I managed multiple, simultaneous, custom pharmacological and phenotyping projects for disorders of the central nervous system. I served as the PI on 3 major IACUCs, working with the IACUC chair and safety committee in an AAALAC-accredited, barrier facility and with supervisors and staff to create and maintain animal use protocols, standard operating procedures, records, and training records. Subsequently, I joined Cohen Veteran Bioscience as a program manager. 

Andre Der-Avakian

Andre Der-Avakian is Assistant Professor of Psychiatry at the University of California San Diego (UCSD) and Associate Member of the American College of Neuropsychopharmacology (ACNP). He is Principal Investigator on research projects funded by grants from the National Institute of Mental Health (NIMH) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) and has managed research contracts and collaborations with industry and non-profit organizations. His lab is focused on developing novel cross-species behavioral and neurophysiological assessments of reward, cognition, and other behaviors in rodents relevant to psychiatric disorders, and using those translational measures to facilitate drug discovery efforts for depression, schizophrenia, and substance use disorders. Andre received his Ph.D. in Neuroscience from the University of Colorado Boulder and he completed a NIMH-sponsored postdoctoral fellowship in the Department of Psychiatry at UCSD.

Prof. Dr. Malcolm Macleod

Malcolm Macleod, BSc(Hons) MBChB PhD FRCP Ed, is Professor of Neurology and Translational Neuroscience at the University of Edinburgh, head of Neurology at Forth Valley Royal Hospital, and Honorary Principal Research Fellow, Florey Neurosciences Unit, Melbourne, Australia.  Prof. Macleod was a founding co-ordinator of the Collaborative Approach to Meta-Analysis and Review of Animal Data in Experimental Studies (CAMARADES), leader in advancing education about systematic reviews in animal research. Prof. Macleod is a member of the UK Home Office Animals in Science Committee.

Publication highlights:

Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, Hirst T, Hemblade R, Bahor Z, Nunes-Fonseca C, Potluru A, Thomson A, Baginskitae J, Egan K, Vesterinen H, Currie GL, Churilov L, Howells DW, Sena ES (2015) Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biol 13 (10): e1002273.

Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Chan AW, Glasziou P (2014) Biomedical research: increasing value, reducing waste. Lancet 383 (9912): 101-4.

Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490 (7419): 187-91.